Healthcare Product Development Business

We conduct research and development, manufacturing, and sales of ethical drugs, diagnostic reagents, and medical devices and materials that contribute to improvement of the quality of life of patients and unmet medical needs.

We develop, manufacture and sell pharmaceuticals that contribute to the improvement of lifestyle-related diseases with a focus on diabetes, high added value generic drugs, blood glucose self-monitoring devices and diagnostic agents with a top share of the domestic market. Some of our factories conduct contract manufacturing for major pharmaceutical manufacturers. Sanwa Kagaku Kenkyusho's own formulation technology has earned high evaluation at home and abroad.

At Sanwa Kagaku Kenkyusho Co., Ltd. we give serious consideration to patient QOL and economic aspects, and develop easy-to-use, safer and more effective medicines.

At Sanwa Kagaku Kenkyusho Co., Ltd. we manufacture essential high-quality diagnostic drugs and diagnostic equipment for ultrasonography, electrocardiography and for testing blood and urine specimens in hospitals and clinics.

At Sanwa Kagaku Kenkyusho's Kumamoto Factory, we carry out contract manufacturing for major pharmaceutical manufacturers in addition to manufacturing our own pharmaceuticals.

As a pharmaceutical manufacturer, our ongoing growth relies on the development of new pharmaceuticals. We view diabetes, and kidney and dialysis-related areas, as areas with substantial unmet medical needs and strong potential as new growth markets. These areas are at the center of our efforts to develop new pharmaceuticals and enhance our pharmaceutical development pipeline.

In August 2021, we launched the UPASITA IV Injection Syringe for Dialysis, a therapeutic agent for secondary hyperparathyroidism, and we are co-promoting it with Kissei Pharmaceutical Co., Ltd., in an effort to penetrate the market. In February 2022, we concluded a license agreement with Crinetics Pharmaceuticals, Inc.^※1 relating to the exclusive development and commercialization of Paltusotine^※2 in Japan, and we will move forward on development.

We are reviewing and restructuring Sanwa Kagaku Kenkyusho’s supply chain as a whole. Taking into account factors such as the direction of new drug development and the increasingly globalized business environment, in September 2022, we transferred the Fukushima Factory, a pharmaceutical manufacturing business location, to Bushu Pharmaceuticals Ltd., which has acquired GMP certification in several countries around the world. We will be jointly employing sophisticated technology and production operations.

Drawing on the strengths we have cultivated as a pharmaceutical manufacturing—high quality, reliable supply, and low cost—the Suzuken Group aims to create new business models and enhance productivity by combining these strengths with its other capabilities and collaborating with partner companies.

Our core medical equipment whose brand name is "Kenz" developed by Suzuken group is testing equipment such as Holter electrocardiographs, blood pressure monitors and stethoscopes. We are boldly taking on challenge to develop the equipment to make testing easier and more accurate as well as no burden and anxiety to patients and have realized the miniaturization of Holter electrocardiographs.

We have constructed systems including the "ISO13485" quality assurance system for medical equipment to meet global quality requirements. Kenz products are used in medical practice in over 30 countries worldwide, mainly in the Asian region, and have received high evaluation from medical institutions around the world.

Kenzmedico Co., Ltd. leverages the Group’s sales marketing capabilities to develop and manufacture not only the Kenz-brand medical devices and supplies sold through Suzuken but also medical devices such as stethoscopes and sphygmomanometers for professional use. In February 2022, we obtained medical equipment certification and insurance coverage for the “Simple Holter,” a test kit that integrates a single-use waterproof Holter electrocardiograph and an electrocardiogram data analysis service. This service is easy to use even at medical institutions that do not have testing experience.